Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
  • Patent number: 11130783
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 28, 2021
    Assignees: Regents of the University of Minnesota, Diabetes-Free, Inc.
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath
  • Patent number: 11129881
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: September 28, 2021
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Patent number: 11130811
    Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 28, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Yao-Bin Liu, Patrick Mayes, Radha Shah Parmar
  • Patent number: 11117976
    Abstract: The present application discloses a previously unknown function of CD24 expressed on a subset of dendritic cells. The invention encompasses regulating CD24 on these cells to regulate erythropoiesis, induce EPO production and levels, increase RBC levels, and to treat, for example, stress-mediated erythropoiesis. The compositions and methods of the invention are useful, for example, in treating anemia.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Virginia Patent Foundation
    Inventors: Thomas J. Braciale, Taeg S. Kim
  • Patent number: 11098131
    Abstract: Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 24, 2021
    Inventors: Ryan Stafford, Alice Yam, John Lee, Stephanie Armstrong, Aaron Sato
  • Patent number: 11078518
    Abstract: Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: August 3, 2021
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Public University Corporation Nara Medical University
    Inventors: Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima
  • Patent number: 11077199
    Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 3, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
  • Patent number: 11072779
    Abstract: The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127?/LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 27, 2021
    Inventors: Natalia Marek-Trzonkowska, Piotr Trzonkowski, Malgorzata Mysliwiec
  • Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Patent number: 11040067
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: June 22, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 10981992
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Patent number: 10919953
    Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: February 16, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
  • Patent number: 10882916
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 5, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Patent number: 10876161
    Abstract: The present invention encompasses methods and kits employing pattern recognition receptor expression as a measure of systemic health in a subject afflicted with an oral health condition. In particular, the present invention is directed to methods involving measurement of the expression levels of one or more Pattern Recognition Receptors including but not limited to Toll Like Receptors, myeloid differentiation primary response gene 88 (MyD88), and Nucleotide Binding oligomerization domain containing protein 1 (NOD1), in a companion animal, e.g., a dog or a cat, afflicted with an oral health condition. The described methods enable evaluation of the systemic health of the animal afflicted with an oral health condition by measuring expression levels of the indicated genes as compared to suitable controls.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 29, 2020
    Assignee: Hills Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Dale S. Scherl
  • Patent number: 10837060
    Abstract: The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: November 17, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Anil K. Panigrahi, Eline Luning Prak
  • Patent number: 10828354
    Abstract: A vaccine preparation comprising an antigen for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, wherein the antigen is linked to a binder of a dermal migratory antigen-presenting cell (APC); and a pharmaceutical preparation comprising an active substance for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, for regional delivery to a target location. The invention further relates to the laser-assisted intradermal administration of antigens accompanied by repeated chemotherapy.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 10, 2020
    Inventors: Reinhard Braun, Dorothea Terhorst, Sandrine Henri, Bernard Malissen, Yoan J. Machado, Mellissa Mayr, Theresa Thalhamer, Veronika Höpflinger, Josef Thalhamer, Richard Weiss
  • Patent number: 10829522
    Abstract: A peptide capable of preventing pathogenic bacteria from colonizing in digestive organs comprises a first domain having an amino acid sequence capable of binding to a minor pilin of IVb fimbriae, and a second domain having an amino acid sequence capable of multimerization, the second domain connect to the first domain via a linker sequence.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 10, 2020
    Inventors: Shota Nakamura, Kazuki Kawahara, Hiroya Oki, Takuya Yoshida, Tadayasu Ohkubo, Yuji Kobayashi, Takahiro Maruno, Daisuke Motooka, Shigeaki Matsuda, Toshio Kodama, Tetsuya Iida, Yasumitsu Tsujino, Shunsuke Fukakusa
  • Patent number: 10809264
    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: October 20, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt
  • Patent number: 10800821
    Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: October 13, 2020
    Inventors: Wenzhi Tian, Deqiang Jing
  • Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • Patent number: 10752902
    Abstract: The disclosure relates to, among other things, agents that modulate the homophilic interaction between two CRACC polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal. Also featured are screening methods for identifying additional agents capable of modulating the activation of an immune cell exposed to an antigen.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: August 25, 2020
    Assignee: Board of Trustees of Michigan State University
    Inventors: Andrea Amalfitano, Yasser A. Aldhamen
  • Patent number: 10695426
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: June 30, 2020
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Leena Das-Young, Keith David Wilner, Steffan Nicholas Ho
  • Patent number: 10688186
    Abstract: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: June 23, 2020
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Patent number: 10689444
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 23, 2020
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 10647770
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 12, 2020
    Inventors: Shiro Shibayama, Masamichi Imai
  • Patent number: 10640567
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 5, 2020
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Patent number: 10624950
    Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 21, 2020
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Patent number: 10610582
    Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 7, 2020
    Assignee: PCI BIOTECH AS
    Inventors: Anders Hogset, Pal Johansen
  • Patent number: 10604567
    Abstract: Disclosed herein are antibodies specific for erythroferrone and assays comprising the antibodies. Also disclosed are methods for using the assays for the diagnosis or monitoring of disease.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 31, 2020
    Inventors: Mark Westerman, Huiling Han, Vaughn Ostland
  • Patent number: 10590195
    Abstract: The present disclosure relates to recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present disclosure also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: March 17, 2020
    Assignee: VACCIBODY AS
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Patent number: 10519242
    Abstract: The present invention provides methods and compositions comprising a heterodimeric antibody comprising a first monomer comprising a first variant heavy chain constant region and an anti-CD4 binding moiety. The heterodimeric antibody also comprises a second monomer comprising: a second variant heavy chain constant region and an anti-CD25 binding moiety. In some cases, the pIs of the first and second variant heavy chain constant regions are at least 0.5 logs apart.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 31, 2019
    Assignee: Xencor, Inc.
    Inventors: Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais
  • Patent number: 10512687
    Abstract: The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (TLR3) and toll like receptor 9 (TLR9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces. In further aspects, disclosed compositions are administered to a mammal in conjunction with an antigen to enhance the immune response of the mammal to the antigen.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 24, 2019
    Assignees: Colorado State University Research Foundation, The Regents of the University of Colorado, a body corporate
    Inventors: Steven Dow, Michael R. Lappin, William H. Wheat, Lyndah Chow, Daniel P. Regan, Thomas J. Anchordoquy
  • Patent number: 10509033
    Abstract: Provided are a method for diagnosing chronic inflammatory demyelinating polyneuropathy (CIDP), in particular, a diagnostic method for specifically diagnosing a group having a specific pathophysiology among CIDPs, and a kit and a biomarker for use in such a diagnosis. The diagnostic method for diagnosing CIDP of the present invention includes a step of measuring an anti-neurofascin 155 antibody contained in a sample.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: December 17, 2019
    Assignee: Kyushu University, National University Corporation
    Inventors: Junichi Kira, Nobutoshi Kawamura, Ryo Yamasaki, Dai Matsuse, Hidenori Ogata
  • Patent number: 10466325
    Abstract: The disclosure relates to a method for determining a sequence information element of a magnetic resonance sequence, a computer program product and an evaluation unit for performing such a method, and also a magnetic resonance device having such an evaluation unit. The method includes a determination of the sequence information element based on at least one pattern of the magnetic resonance sequence.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: November 5, 2019
    Assignee: Siemens Healthcare GmbH
    Inventors: Andreas Greiser, David Grodzki, Daniel Nico Splitthoff
  • Patent number: 10458986
    Abstract: The invention relates to senescent cell biomarkers and the uses thereof. The invention also extends to methods and kits for detecting senescence, and drug conjugates and pharmaceutical compositions for killing senescent cells.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: October 29, 2019
    Inventor: Salvador Macip
  • Patent number: 10444241
    Abstract: The application provides methods of diagnosis, prognosis, prophylasxis and treatment of CD30+ cancers.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: October 15, 2019
    Inventors: Tina Albertson, Maria L. Smith
  • Patent number: 10435475
    Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: October 8, 2019
    Inventors: Marek Honczarenko, Vaishali Shah, Xiaoni Liu, Wendy L. Trigona, Rong Shi, Suzanne J. Suchard, Karen D. Price, Linda M. Gustavson
  • Patent number: 10420846
    Abstract: A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 24, 2019
    Assignee: Immunocore Limited
    Inventors: Bent Karsten Jakobsen, Annelise Brigitte Vuidepot, Yi Li
  • Patent number: 10420751
    Abstract: The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 24, 2019
    Assignee: MedRegen, LLC
    Inventors: Zhaoli Sun, Xuhang Li
  • Patent number: 10408820
    Abstract: The application describes an assay for the identification of small molecule modulators of integrin CD11b/CD18 and small molecules capable of modulating activity of this receptor. Such compounds may be used in certain embodiments for treating a disease or condition selected from inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening associated with vascular injury, bullous pemphigoid, neonatal obstructive nephropathy, and cardiovascular disease, or in other embodiments for the treatment of a disease or condition selected from immune deficiency, acquired immune deficiency syndrome (AIDS), myeloperoxidase deficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease, hyper-IgM syndromes, leukocyte adhesion deficiency, Chediak-Higashi syndrome, and severe combined immunodeficiency.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: September 10, 2019
    Inventors: Vineet Gupta, M. Amin Arnaout
  • Patent number: 10407513
    Abstract: A multivalent antibody fusion protein which comprises an immunoglobulin moiety, for example a Fab or Fab? fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, wherein the two single domain antibodies are linked by a disulfide bond. There is also provided particular dual specificity antibody fusion proteins comprising a Fab or Fab? fragment and one or more single domain antibodies which may be stabilized by a disulfide bond therebetween.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: September 10, 2019
    Inventors: Ralph Adams, Laura Hancock, Sam Philip Heywood
  • Patent number: 10400043
    Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: September 3, 2019
    Assignee: Biogen, Inc.
    Inventors: Christine A. White, Antonio J. Grillo-Lopez
  • Patent number: 10383917
    Abstract: Provided is an agent for the treatment of an autoimmune disease, the agent comprising C1q/TNF-related protein 3 (CTRP3), and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRPb3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: August 20, 2019
    Inventors: Yoichiro Iwakura, Masanori Murayama
  • Patent number: 10350242
    Abstract: The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about 72 hours. The storage method enables the cells to be manufactured at a processing facility and shipped to a point of care site. The invention also includes compositions that have been stored in non-nutritive buffer at storage temperatures while maintaining the functional characteristics.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: July 16, 2019
    Inventor: Michael Har-Noy
  • Patent number: 10336829
    Abstract: Provided are compounds having the Formula I: pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and their use in the intracellular delivery of antibodies.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: July 2, 2019
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Yanwen Fu, Gunnar Jörg Floris Kaufmann, Heehyoung Lee, Ingale Sampat Lalaso
  • Patent number: 10316095
    Abstract: Formulations of anti-VLA-1 antibodies are described.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: June 11, 2019
    Assignee: Santarus, Inc.
    Inventors: Adam Jeremy Fowler, Craig Michael Bowe, Wayne Curtis Yount, Nathan Jeremy Cobb, Timothy Martin Kelly
  • Patent number: 10316085
    Abstract: The present invention relates in part to the discovery of genes that are deregulated in cancer stem cells (e.g., melanoma stem cells). In some aspects, methods for treating individuals having melanoma are provided; the methods involve modulating (e.g., inducing, inhibiting, etc.) the activity of the cancer stem cell associated genes. In other aspects, cell surface genes that are upregulated in melanoma stem cells are targeted for the selective isolation, detection, and killing of cancer stem cells in melanoma. Other aspects of the invention relate to reagents, arrays, compositions, and kits that are useful for diagnosing and treating melanoma.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 11, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Markus H. Frank, Natasha Y. Frank
  • Patent number: 10293059
    Abstract: This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding a therapeutic gene that blocks allergic reactions. The invention is also directed to a composition comprising the vector and method of using the vector to reduce or inhibit an immune response or allergic reaction to an allergen in a mammal.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: May 21, 2019
    Inventors: Ronald G. Crystal, Odelya E. Pagovich, Maria J. Chiuchiolo
  • Patent number: 10287356
    Abstract: The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 14, 2019
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu